Related Experiment Video
Updated: Nov 1, 2025
07:24
Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR
Published on: April 8, 2013
24.5K
Optimising the Heart Failure Treatment Pathway: The Role of SGLT2 Inhibitors
Marc Evans1, Angharad R Morgan2, Zaheer Yousef3
1Diabetes Resource Centre, University Hospital Llandough, Penlan Road, Llandough, Cardiff, CF64 2XX, UK. marclyndon1@hotmail.com.
Drugs
|June 23, 2021
Summary
Sodium-glucose cotransporter 2 (SGLT2) inhibitors, initially for diabetes, now offer significant benefits for heart failure with reduced ejection fraction (HFrEF). This review supports wider, safe use of SGLT2 inhibitors in HFrEF patients.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Sodium-glucose cotransporter 2 (SGLT2) inhibitors were developed for diabetes management.
- Emerging evidence shows SGLT2 inhibitors benefit patients with heart failure with reduced ejection fraction (HFrEF), irrespective of diabetes status.
Purpose of the Study:
- To address the lack of familiarity with SGLT2 inhibitors for heart failure (HF) indication.
- To provide expert guidance on integrating SGLT2 inhibitors into HF treatment pathways.
- To encourage safe and expanded use of SGLT2 inhibitors in HFrEF patients.
Main Methods:
- Consensus expert opinion.
- Review of available clinical trial evidence.
- Analysis of drug label indications.
Main Results:
- SGLT2 inhibitors demonstrate efficacy in preventing worsening heart failure events.
- These drugs improve quality of life and reduce mortality in HFrEF.
- Clinical trial data supports favorable outcomes for HFrEF patients.
Conclusions:
- SGLT2 inhibitors are valuable therapeutic agents for HFrEF.
- Increased awareness and understanding are needed among healthcare providers treating HF.
- Practical guidance is provided to facilitate appropriate prescribing and safe utilization.
Related Concept Videos
01:30Heart Failure V: Medical Management
60
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
60
01:22Heart Failure VI: Adjunct Therapies
68
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
68
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
632
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
632
01:26Heart Failure Drugs: Inotropic Agents
885
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
885
01:22Heart Failure Drugs: Diuretics
575
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
575
01:30Heart Failure VII: Nursing Interventions
207
The first step in nursing management of a patient with heart failure involves thoroughly assessing the patient's medical history.Subjective Data: Obtain the patient's medical history of coronary artery disease, hypertension, myocardial infarction, and symptoms like dyspnea, orthopnea, and paroxysmal nocturnal dyspnea.Objective Data: Conduct a physical examination to identify findings such as jugular vein distention, pulmonary crackles, tachycardia, murmurs, peripheral edema, and vital signs,...
207